FAST研究:唑贝妥昔单抗联合EOX一线治疗CLDN18.2阳性晚期胃及胃食管腺癌的随机II期结果
FAST是一项随机II期研究,入组CLDN18.2中至强表达≥40%肿瘤细胞的晚期胃/胃食管交界及食管腺癌患者,比较唑贝妥昔单抗联合EOX与EOX alone一线治疗。结果显示联合组PFS和OS均显著改善,≥3级不良事件总体无实质增加,唑贝妥昔单抗800/600 mg/m2方案正进入III期评估。
要点
- 唑贝妥昔单抗+EOX较EOX alone显著改善PFS(HR=0.44)和OS(HR=0.55)。
- CLDN18.2中至强表达≥70%肿瘤细胞患者PFS获益保留(HR=0.38)。
- 联合组多数不良事件为1-2级,≥3级不良事件总体无实质增加。
核心结论
- 在CLDN18.2表达的晚期胃/胃食管交界及食管腺癌患者中,唑贝妥昔单抗联合一线EOX较EOX alone延长PFS和OS。
- 唑贝妥昔单抗+EOX总体耐受,不良事件可控。
研究设计与样本
- FAST为随机II期研究,入组年龄≥18岁、CLDN18.2中至强表达≥40%肿瘤细胞的晚期胃/胃食管交界及食管腺癌患者。
- 第1组接受EOX每3周(n=84),第2组接受唑贝妥昔单抗+EOX(负荷800 mg/m2后600 mg/m2每3周,n=77)。
- 第3组为入组启动后新增的探索组,接受唑贝妥昔单抗+EOX 1000 mg/m2每3周(n=85)。
- 主要终点为PFS,OS为次要终点。
主要发现
- 总体人群中,唑贝妥昔单抗+EOX(第2组)较EOX alone(第1组)显著改善PFS(HR=0.44;95%CI 0.29-0.67;P<0.0005)。
- 总体人群中,唑贝妥昔单抗+EOX(第2组)较EOX alone(第1组)显著改善OS(HR=0.55;95%CI 0.39-0.77;P<0.0005)。
- CLDN18.2中至强表达≥70%肿瘤细胞患者中,唑贝妥昔单抗+EOX(第2组)较EOX alone(第1组)PFS获益保留(HR=0.38;95%CI 0.23-0.62;P<0.0005)。
- 第3组总体人群较第1组PFS显著改善(HR=0.58;95%CI 0.39-0.85;P=0.0114),但高CLDN18.2表达患者中未达显著,两组人群OS均无显著改善。
- 唑贝妥昔单抗+EOX相关多数不良事件(恶心、呕吐、中性粒细胞减少、贫血)为1-2级,≥3级不良事件总体无实质增加。
关键数值与推荐
- 入组要求CLDN18.2中至强表达于≥40%肿瘤细胞。
- 第2组唑贝妥昔单抗剂量为负荷800 mg/m2后600 mg/m2每3周。
- 第3组唑贝妥昔单抗剂量为1000 mg/m2每3周。
- PFS获益在CLDN18.2中至强表达≥70%肿瘤细胞患者中保留。
临床怎么用
- 对于CLDN18.2中至强表达≥40%肿瘤细胞的晚期胃/胃食管交界及食管腺癌患者,一线可考虑唑贝妥昔单抗联合EOX。
- 唑贝妥昔单抗800/600 mg/m2联合EOX方案基于总体人群及CLDN18.2≥70%肿瘤细胞患者的临床获益正进行III期评估。
- 治疗期间需关注恶心、呕吐、中性粒细胞减少和贫血等不良事件,多数为1-2级。
局限性
- 本研究为随机II期研究,样本量有限。
- 第3组为入组启动后新增的探索性组,非初始随机设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms. PATIENTS AND METHODS: The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/m2 then 600 mg/m2 Q3W) (arm 2, n = 77). Arm 3 (exploratory) was added after enrolment initiation (zolbetuximab + EOX 1000 mg/m2 Q3W, n = 85). The primary endpoint was progression-free survival (PFS) and overall survival (OS) was a secondary endpoint. RESULTS: In the overall population, both PFS [hazard ratio (HR) = 0.44; 95% confidence interval (CI), 0.29-0.67; P < 0.0005] and OS (HR = 0.55; 95% CI, 0.39-0.77; P < 0.0005) were significantly improved with zolbetuximab + EOX (arm 2) compared with EOX alone (arm 1). This significant PFS benefit was retained in patients with moderate-to-strong CLDN18.2 expression in ≥70% of tumour cells (HR = 0.38; 95% CI, 0.23-0.62; P < 0.0005). Significant improvement in PFS was also reported in the overall population of arm 3 versus arm 1 (HR = 0.58; 95% CI, 0.39-0.85; P = 0.0114) but not in high CLDN18.2-expressing patients; no significant improvement in OS was observed in either population. Most adverse events (AEs) related to zolbetuximab + EOX (nausea, vomiting, neutropenia, anaemia) were grade 1-2. Grade ≥3 AEs showed no substantial increases overall (zolbetuximab + EOX versus EOX alone). CONCLUSIONS: In advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients expressing CLDN18.2, adding zolbetuximab to first-line EOX provided longer PFS and OS versus EOX alone. Zolbetuximab + EOX was generally tolerated and AEs were manageable. Zolbetuximab 800/600 mg/m2 is being evaluated in phase III studies based on clinical benefit observed in the overall population and in patients with moderate-to-strong CLDN18.2 expression in ≥70% of tumour cells.
引用
- Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021. PMID: 33610734. doi:10.1016/j.annonc.2021.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。